Genmab sales of Darzalex exceed expectations in Q3

Third quarter sales figures for Darzalex, which Genmab has in-licensed to Johnson & Johnson, are far better than previous estimates.

Photo: Joost Melis / Genmab / PR

The Genmab-developed treatment for multiple myeloma, a type of bone marrow cancer, has exceeded expectations in the third quarter of the year, according to Q3 reports from Johnson & Johson, which obtained the drug through an in-licensing agreement.

In June, August and September, Darzalex sales have have earned USD 1.58bn compared to analysts' earlier estimates of USD 1.45bn, according to data collected by Bloomberg News.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs